Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
- Conditions
- Stage I Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Limited Stage Lung Small Cell Carcinoma
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyProcedure: Biospecimen CollectionDrug: AtezolizumabDrug: CarboplatinDrug: CisplatinDrug: EtoposideRadiation: Intensity-Modulated Radiation TherapyOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 544
- Registration Number
- NCT03811002
- Locations
- 🇺🇸
Aspirus Regional Cancer Center, Wausau, Wisconsin, United States
🇺🇸Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸Aurora West Allis Medical Center, West Allis, Wisconsin, United States
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT03802240
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: PlaceboDrug: DurvalumabDrug: CarboplatinDrug: CisplatinDrug: PemetrexedDrug: PaclitaxelDrug: GemcitabineProcedure: Surgery
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 826
- Registration Number
- NCT03800134
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Piedmont Cancer Institute
- Registration Number
- NCT03797443
- Locations
- 🇺🇸
Piedmont Cancer Institute, Newnan, Georgia, United States
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
- Conditions
- Neoplasm, EsophagealSquamous Cell Carcinoma
- Interventions
- Drug: PaclitaxelDrug: OxaliplatinDrug: CisplatinDrug: 5-FURadiation: Intensity-modulated radiotherapyDrug: LeucovorinDevice: PET
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Mian XI
- Target Recruit Count
- 216
- Registration Number
- NCT03791905
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- GanglioneuroblastomaHigh Risk Neuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: DexrazoxaneBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideRadiation: External Beam Radiation TherapyDrug: IsotretinoinDrug: MelphalanBiological: SargramostimDrug: ThiotepaDrug: TopotecanDrug: Vincristine
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 649
- Registration Number
- NCT03783442
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
- Conditions
- Gastric, or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 997
- Registration Number
- NCT03777657
- Locations
- 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇫🇷CHU Besançon - Hôpital Jean Minjoz, Besançon, France
🇫🇷Hôpital de la Timone, Marseille, France
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
- Conditions
- Muscle Invasive Bladder CarcinomaBladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Procedure: Biopsy of BladderDrug: AtezolizumabDrug: CisplatinProcedure: Computed TomographyProcedure: CystoscopyDrug: GemcitabineDrug: FluorouracilProcedure: Magnetic Resonance ImagingDrug: MitomycinOther: Quality-of-Life AssessmentRadiation: Radiation TherapyOther: Survey AdministrationProcedure: Transurethral Resection of Bladder Tumor
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 475
- Registration Number
- NCT03775265
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Henry Ford Saint John Hospital - Macomb Medical, Macomb, Michigan, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
- Conditions
- Advanced CholangiocarcinomaFGFR2 Gene Mutation
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03773302
- Locations
- 🇺🇸
Parkland Health and Hospital System, Dallas, Texas, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.